31176103|t|Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signalling.
31176103|a|BACKGROUND: Obesity is commonly found to be co-morbid with type 2 Diabetes Mellitus. In obese diabetic patients, TLR-2 receptor induced inflammation leads to the development of insulin resistance (IR). Furthermore, the IR is considered to be the most important cause for promoting cognitive decline which is evident in brain of patients with Alzheimer's disease related dementia (ADRD). METHODS: In this study, the effect of alpha-lipoic acid (ALA) has been examined in rodent model of zymosan induced insulin resistance and cognitive deficits, targeting at TLR-2 signalling. TLR-2 agonist, Zymosan initiates inflammatory cascade, resulting in IR and cognitive dysfunction. Zymosan (50 mg/kg ip) was given to mice on 1st, 8th, 15th and 22nd day to induce IR which was confirmed by hyperglycaemia, hyperinsulinemia, hyperlipidimea, increased glycated haemoglobin and HOMA-IR. Further the cognitive performance was assessed in Morris water maze revealing cognitive deficit in zymosan treated mice. RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus. ALA also increased adiponectin level and reduced body weight. Combination of ALA (100 mg/kg, ip) with metformin (100 mg/kg, ip) exhibited a potentiating effect in improving cognitive performance and insulin signalling. CONCLUSION: The findings of the study supported the hypothesis that TLR-2 induced inflammation leads to insulin resistance and cognitive impairment and provides an evidence for the therapeutic effect of ALA in IR and ADRD patients.
31176103	0	17	Alpha lipoic acid	Chemical	MESH:D008063
31176103	22	31	metformin	Chemical	MESH:D008687
31176103	66	84	insulin resistance	Disease	MESH:D007333
31176103	89	106	cognitive deficit	Disease	MESH:D003072
31176103	124	128	TLR2	Gene	24088
31176103	153	160	Obesity	Disease	MESH:D009765
31176103	200	224	type 2 Diabetes Mellitus	Disease	MESH:D003924
31176103	229	243	obese diabetic	Disease	MESH:D009765
31176103	244	252	patients	Species	9606
31176103	277	289	inflammation	Disease	MESH:D007249
31176103	318	336	insulin resistance	Disease	MESH:D007333
31176103	338	340	IR	Disease	MESH:D007333
31176103	360	362	IR	Disease	MESH:D007333
31176103	422	439	cognitive decline	Disease	MESH:D003072
31176103	469	477	patients	Species	9606
31176103	483	519	Alzheimer's disease related dementia	Disease	MESH:D000544
31176103	521	525	ADRD	Disease	MESH:D000544
31176103	566	583	alpha-lipoic acid	Chemical	MESH:D008063
31176103	585	588	ALA	Chemical	MESH:D008063
31176103	627	634	zymosan	Chemical	MESH:D015054
31176103	643	661	insulin resistance	Disease	MESH:D007333
31176103	666	684	cognitive deficits	Disease	MESH:D003072
31176103	699	704	TLR-2	Gene	24088
31176103	717	722	TLR-2	Gene	24088
31176103	732	739	Zymosan	Chemical	MESH:D015054
31176103	750	762	inflammatory	Disease	MESH:D007249
31176103	785	787	IR	Disease	MESH:D007333
31176103	792	813	cognitive dysfunction	Disease	MESH:D003072
31176103	815	822	Zymosan	Chemical	MESH:D015054
31176103	850	854	mice	Species	10090
31176103	896	898	IR	Disease	MESH:D007333
31176103	922	936	hyperglycaemia	Disease	
31176103	938	954	hyperinsulinemia	Disease	MESH:D006946
31176103	956	970	hyperlipidimea	Disease	
31176103	1012	1014	IR	Disease	MESH:D007333
31176103	1094	1111	cognitive deficit	Disease	MESH:D003072
31176103	1115	1122	zymosan	Chemical	MESH:D015054
31176103	1131	1135	mice	Species	10090
31176103	1167	1170	ALA	Chemical	MESH:D008063
31176103	1280	1284	mice	Species	10090
31176103	1299	1317	insulin resistance	Disease	MESH:D007333
31176103	1319	1333	corticosterone	Chemical	MESH:D003345
31176103	1335	1339	IL-6	Gene	16193
31176103	1348	1368	acetylcholinesterase	Gene	11423
31176103	1440	1443	ALA	Chemical	MESH:D008063
31176103	1459	1470	adiponectin	Gene	11450
31176103	1517	1520	ALA	Chemical	MESH:D008063
31176103	1542	1551	metformin	Chemical	MESH:D008687
31176103	1727	1732	TLR-2	Gene	24088
31176103	1741	1753	inflammation	Disease	MESH:D007249
31176103	1763	1781	insulin resistance	Disease	MESH:D007333
31176103	1786	1806	cognitive impairment	Disease	MESH:D003072
31176103	1862	1865	ALA	Chemical	MESH:D008063
31176103	1869	1871	IR	Disease	MESH:D007333
31176103	1876	1880	ADRD	Disease	MESH:D000544
31176103	1881	1889	patients	Species	9606
31176103	Negative_Correlation	MESH:D008063	MESH:D003072
31176103	Positive_Correlation	MESH:D015054	MESH:D003072
31176103	Negative_Correlation	MESH:D008687	MESH:D003072
31176103	Association	MESH:D008063	24088
31176103	Association	MESH:D008687	24088
31176103	Positive_Correlation	MESH:D008063	11450
31176103	Cotreatment	MESH:D008063	MESH:D008687
31176103	Positive_Correlation	MESH:D007249	24088
31176103	Negative_Correlation	MESH:D008687	MESH:D007333
31176103	Negative_Correlation	MESH:D008063	16193
31176103	Negative_Correlation	MESH:D008063	MESH:D007333
31176103	Association	MESH:D007333	24088
31176103	Positive_Correlation	MESH:D015054	MESH:D007333
31176103	Positive_Correlation	MESH:D015054	MESH:D007249
31176103	Negative_Correlation	MESH:D008063	11423
31176103	Positive_Correlation	MESH:D015054	MESH:D006946
31176103	Negative_Correlation	MESH:D003345	MESH:D008063
31176103	Association	MESH:D003072	24088
31176103	Negative_Correlation	MESH:D008063	MESH:D000544
31176103	Positive_Correlation	MESH:D015054	24088

